Dr. Reddy's Laboratories Limited (NSE: DRREDDY)
India
· Delayed Price · Currency is INR
1,224.40
-65.00 (-5.04%)
Jan 24, 2025, 3:30 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 83.59B INR in the quarter ending December 31, 2024, with 15.85% growth. This brings the company's revenue in the last twelve months to 311.31B, up 14.74% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
311.31B
Revenue Growth
+14.74%
P/S Ratio
n/a
Revenue / Employee
11.51M
Employees
27,048
Market Cap
1,020.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 503.08B |
Divi's Laboratories | 86.14B |
Cipla | 262.64B |
Mankind Pharma | 110.18B |
Apollo Hospitals Enterprise | 204.69B |
Zydus Lifesciences | 214.84B |
Aurobindo Pharma | 302.95B |
Alkem Laboratories | 128.32B |
Dr. Reddy's Laboratories News
- 16 hours ago - Dr. Reddy's Laboratories Limited 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 19 hours ago - Nifty 50 top losers today on January 24: Dr. Reddy’s Laboratories, Trent, and Mahindra & Mahindra and more - Business Upturn
- 1 day ago - Dr Reddy's Laboratories CEO: 'very positive outlook' for Indian pharma industry despite Trump 2.0 - CNBC
- 1 day ago - Dr Reddy’s shares fall over 5% following Q3 FY25 results - Business Upturn
- 1 day ago - Dr Reddy’s Q3 Results: CLSA raises FY25-27 revenue and margin estimates; check target price - Business Upturn
- 1 day ago - CLSA reiterates Sell call on Dr Reddy’s following Q3 results missing estimates - Business Upturn
- 1 day ago - HSBC maintains Hold call on Dr Reddy’s after Q3FY25 earnings, target at Rs 1,250 - Business Upturn
- 1 day ago - Hindustan Unilever, Dr Reddy’s Laboratories: Stocks on radar today - The Times of India